Moleculera
1 known investors
Moleculera develops precision medicine technologies for identifying and treating immune-mediated disorders, including neuropsychiatric and cardiovascular conditions, using blood-based autoantibody testing panels, biobank data, and biomarker identification. The company serves healthcare providers and patients seeking diagnosis of treatment-resistant neuropsychiatric and autoimmune disorders.